• +33 3 74 02 03 03

StarkLabs was the first to develop
an alternate method for removal of senescent cells in age-related pathologies using immunotherapy.
StarkLabs was the first to develop
an alternate method for removal of senescent cells in age-related pathologies using immunotherapy.

Home – StarkLabs

StarkLabs was founded in July 2018 by Dr. Thierry Mathieu.

“Our goal is to become a benchmark in the field of normal and pathological human aging in order to improve quality of life.”

Thierry Mathieu,

Founder, President, MD, MSc

Research Overview

Each year almost 60M people die from non-contagious chronic illnesses, all of which are linked to aging (World Health Organization). Great progress has been made in recent decades in understanding the molecular mechanisms behind the causes of age-related pathologies, in particular cellular senescence. The persistent accumulation of senescent cells appears to be one of the contributors to aging.

STARKLABS was the first team to develop an alternate method for the depletion of senescent cells in age-related pathologies using immunotherapy. We believe that selective senescent cell destruction is the key to achieving successful clinical outcomes which will result in a longer lifespan in good health.

The French government has granted STARKLABS with the “Jeune Entreprise Innovante” label in recognition for our innovative research.  In addition, bpifrance  (the “Banque Publique d’Investissement”) has supported our research pipeline with an initial grant.   

Our Pipeline

The first pathology StarkLabs will focus on is Idiopathic pulmonary fibrosis (IPF).

There is growing evidence in the scientific literature that clearly indicates the central role of senescent cells in the pathophysiology of this disease.

Our research program for the next few years will therefore focus on the discovery and validation of patient-derived senescence target markers linked to this pathology.

The Team